Back to Atlas
CTransientStandard research/education caution
CMP-0263
Approved some regions
Acipimox
Metabolic
Reduces free fatty acid release and modulates lipid metabolism
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Small molecule
- Primary mechanism
- Nicotinic acid receptor/HCA2 agonism; anti-lipolytic
- Primary market use
- Dyslipidemia / metabolic research
Pharmacology
- Molecular weight (Da)
- 154.1
- Oral bioavailability
- High
- Half-life
- ~2 h
- Route tags
- Route-dependent / verify
- Evidence level
- Approved/Clinical
- Clinical status
- Approved some regions
- Value-for-money score
- 6 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Requires ongoing pharmacologic exposure